Compare PRA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRA | IOVA |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2000 | 2008 |
| Metric | PRA | IOVA |
|---|---|---|
| Price | $24.75 | $3.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $25.00 | $9.00 |
| AVG Volume (30 Days) | 890.1K | ★ 13.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $1,098,028,000.00 | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | N/A | $40.31 |
| P/E Ratio | $24.93 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.79 | $1.64 |
| 52 Week High | $24.85 | $5.63 |
| Indicator | PRA | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 43.04 |
| Support Level | $23.88 | $2.03 |
| Resistance Level | $24.79 | $4.33 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 82.84 | 12.14 |
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in four segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.